Loss of lung function after chemo-radiotherapy for NSCLC measured by perfusion SPECT/CT: Correlation with radiation dose and clinical morbidity

Figures & data

Figure 1. Population composite perfusion loss at three months after radiotherapy in different dose bins.

Table I. Patient characteristics (n = 45).

	N (%)
Age (years) median (range)	67 (43–84)
Sex
Male	25 (56)
Female	20 (44)
Clinical stage
I–II	3 (7)
III	31 (69)
IV	2 (4)
Recurrent	9 (20)
GTV (cm^3) median (range)	37 (1.2–316)
Radiation dose (Gy) median (range)	66 (60–66)
Mean lung dose (Gy) (SEM)	12.8 (0.7)

GTV, gross tumour volume; SEM, standard error of the mean.

Figure 2. Individual perfusion data for 45 patients with SPECT available at three-month follow-up. Mean percent perfusion reduction in different dose bins in patients who developed symptomatic radiation pneumonitis grade 2–5 and those who did not. Error bars represent 1 standard error.

Figure 3. Regional perfusion reduction in 21–40 Gy dose bin for each patient and the grade of radiation pneumonitis.

Figure 4. Kaplan-Meier analysis of risk of radiation pneumonitis according to perfusion reduction (bold line) or increase (dotted line) in the total lung at three months after radiotherapy. Number of patients at risk at different time points is shown.